Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Current cancer immunotherapy has limited response rates in a large variety of solid tumors partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor microenvironment (ITM). A number of clinical cancer treatment modalities, including radiotherapy, chemotherapy, photothermal and photodynamic therapy, have been shown to elicit immunogenicity by inducing immunogenic cell death (ICD). However, ICD-based immunotherapy is restricted by the ITM limiting its efficacy in eliciting a long-term antitumor immune response, and by severe systemic toxicity. To address these challenges, nanomedicine-based drug delivery strategies have been exploited for improving cancer immunotherapy by boosting ICD of the tumor cells. Nanosized drug delivery systems are promising for increasing drug accumulation at the tumor site and codelivering ICD inducers and immune inhibitors to simultaneously elicit the immune response and relieve the ITM. This review highlights the recent advances in nanomedicine-based immunotherapy utilizing ICD-based approaches. A perspective on the clinical translation of nanomedicine-based cancer immunotherapy is also provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Schematic of OXA-loaded DHA NCPs (OxPt/DHAs) with synergistic antitumor activity by inducing ICD. a Chemical structure and synergistic mechanism of tumor inhibition; b Confocal images of cell surface localization of CRT upon exposure to OxPt/DHAs; c. Tumor growth over time with OxPt/DHAs or combination therapy with checkpoint blockade (anti-PD-L1) in a mouse model of CT26 colorectal tumor. Adapted with permission from [44]. Copyright (2019) Nature Publishing Group.](https://figures.cochat.ai/paper-figures/b9b50b44249543e2a9c8a40c4decb8b5/engineering-nanomedicines-through-boosting-immunogenic-cell-death-for-improved-figure-2.jpg)
![Fig. 3 Schematic illustration of shedding prodrug vesicles for cancer immunotherapy. a The preparation procedure for enzyme-activatable prodrug vesicles (EAPV) designed to codeliver PEGylated PS and an IDO-1 inhibitor (NLG919); b The mechanisms by which EAPVs enhance antitumor efficacy via synergic triggering of ICD and combating IDO-1-mediated adaptive immune resistance; c Immunofluorescence image of CRT expressed on the surface of tumor cells in the CT26 tumor xenograft model (scale bar = 50 μm); d Immunofluorescence image of HMGB1 release from tumor cells in the CT26 tumor xenograft model (scale bar = 25 μm); e The ratio of mature DCs in tumor-draining lymph nodes; f The number of intratumor infiltrating T lymphocytes in tumor tissue; g Kyn to Trp molar ratio determined for the CT26 tumor tissue; and h Tumor growth curves of the CT26 xenograft tumors. Adapted with permission from [86]. Copyright (2019) American Chemical Society.](https://figures.cochat.ai/paper-figures/3033811679c24dc2b1ebfa80c9622a81/engineering-nanomedicines-through-boosting-immunogenic-cell-death-for-improved-figure-3.jpg)
![Fig. 4 Schematic of LINC for cancer immunotherapy. a The chemical structures and self-assembly process of the LINC; b The mechanisms of NIR light-inducible nanoparticles that induce ICD and reprogram the immunosuppressive tumor microenvironment; c CRT expression; d Intratumoral infiltration of CD8+ T cells; and hematoxylin and eosin (H&E) staining of the lung sections collected from the (e) saline and (f) LINCL-treated mouse groups, respectively. Adapted with permission from [88]. Copyright (2019) John Wiley & Sons, Inc.](https://figures.cochat.ai/paper-figures/600a6f6a9d2545019e93ae8fb1750b55/engineering-nanomedicines-through-boosting-immunogenic-cell-death-for-improved-figure-4.jpg)
![Fig. 5 Schematic of sHDL-DOX to enhance cancer immunotherapy by combining ICD and αPD-1. a The chemical structure and self-assembly process of a sHDL; b The mechanism of sHDL-triggered ICD-mediated antitumor immunity synergized with ICB. The level of CRT cell surface expression in c CT26 and d MC38 tumor models; e tumor volume over time and f Lung metastasis in CT26 tumor-bearing mice. Adapted with permission from [91]. Copyright (2019) Science Publishing Group.](https://figures.cochat.ai/paper-figures/e5626a00986a45d891e6ef6a222eb6ed/engineering-nanomedicines-through-boosting-immunogenic-cell-death-for-improved-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Research works printed but not linked: 2
- Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. · DOI · Paper page
- Gao J, Wang WQ, Yu HJ. Acid-activatable polymeric drug delivery systems for cancer therapy. Acta Pharm Sin. 2019;50:1156–66.
Cited by
Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 680
Cheng, L., Zhang, X., Tang, J., Lv, Q., & Liu, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120964 · Cited by 303
Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future
Sen, S., Won, M., Levine, M. S., Noh, Y., Sedgwick, A. C., Kim, J. S., Sessler, J. L., & Arambula, J. F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00417d · Cited by 297
Immunogenic Cell Death Induction by Ionizing Radiation
Zhu, M., Yang, M., Zhang, J., Yin, Y., Fan, X., Zhang, Y., Qin, S., Zhang, H., & Yu, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705361 · Cited by 291
Smart drug delivery systems for precise cancer therapy
Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.013 · Cited by 233
Self-citation
Metadata
- Authors
- Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J.
- Affiliations
- Chinese Academy of Sciences (CN)
- UNSW Sydney (AU)
- Venue
- Acta Pharmacologica Sinica
- Published
- 2020-04-21
- Volume
- 41
- Issue
- 7
- Pages
- 986-994
- ISSN
- 0253-9756 (ISSN-L)
- 1671-4083
- 1745-7254
- PMC
- PMC7470797
- OpenAlex
- W3016713923
- Cited by
- 203
- References
- 96
- Citations by year
- 2026: 65 · 2025: 25 · 2024: 25 · 2023: 28 · 2022: 29 · 2021: 22 · 2020: 8
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-08-03)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Pharmacologica Sinica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Funders
- University of New South Wales
- National Natural Science Foundation of China (31900990, 51873228, 81521005, 31671024)
- Chinese Academy of Sciences (2014218)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2014218)
- Youth Innovation Promotion Association
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immunogenic cell death, cancer immunotherapy, nanomedicine, tumor microenvironment, immunosuppression, immune checkpoint inhibitors, solid tumors, clinical translation
- MeSH terms
- Immunogenic Cell Death, Antineoplastic Agents, Humans, Immunotherapy, Neoplasms, Photochemotherapy, Drug Delivery Systems, Nanomedicine, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41401-020-0400-z
- The paper
- Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020). Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-020-0400-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.